AR049216A1 - Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadas - Google Patents
Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadasInfo
- Publication number
- AR049216A1 AR049216A1 ARP050102363A ARP050102363A AR049216A1 AR 049216 A1 AR049216 A1 AR 049216A1 AR P050102363 A ARP050102363 A AR P050102363A AR P050102363 A ARP050102363 A AR P050102363A AR 049216 A1 AR049216 A1 AR 049216A1
- Authority
- AR
- Argentina
- Prior art keywords
- cholesterol
- treatment
- cardiovascular diseases
- compositions
- hyperlipidemia
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 8
- 235000012000 cholesterol Nutrition 0.000 title abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Composiciones adaptadas para mejorar el transporte inverso de colesterol en mamíferos. Las composiciones son adecuadas para una administracion oral y de utilidad en el tratamiento y/o prevencion de hipercolesterolemia, aterosclerosis y enfermedades cardiovasculares asociadas. Composiciones adaptadas para mejorar el transporte inverso de colesterol en mamíferos. Las composiciones son adecuadas para una administracion oral y de utilidad en el tratamiento y/o prevencion de hipercolesterolemia, aterosclerosis y enfermedades cardiovasculares asociadas. Reivindicacion 1: Un mediador del transporte inverso de colesterol, que comprende la estructura de formula (1), donde A, B y C pueden estar en cualquier orden y donde A comprende un aminoácido o un análogo del mismo, que comprende un grupo ácido o un bioisostero del mismo; B comprende un grupo aromático o lipofílico que comprende un inhibidor de la HMG CoA reductasa o un análogo del mismo; y C comprende un aminoácido o un análogo del mismo, que comprende un grupo básico o un bioisostero del mismo; donde al menos uno de los grupo alfa-amino o alfa-carboxilo han sido eliminados de sus respectivos aminoácidos amino o carboxilo terminales o análogos de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57822704P | 2004-06-09 | 2004-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049216A1 true AR049216A1 (es) | 2006-07-05 |
Family
ID=34981590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102363A AR049216A1 (es) | 2004-06-09 | 2005-06-09 | Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060009487A1 (es) |
| EP (1) | EP1753724A1 (es) |
| JP (1) | JP2008502736A (es) |
| KR (1) | KR20070026598A (es) |
| CN (1) | CN1968928A (es) |
| AR (1) | AR049216A1 (es) |
| AU (1) | AU2005255011A1 (es) |
| BR (1) | BRPI0511822A (es) |
| CA (1) | CA2568394A1 (es) |
| IL (1) | IL179210A0 (es) |
| MX (1) | MXJL06000069A (es) |
| NO (1) | NO20070139L (es) |
| PE (1) | PE20050986A1 (es) |
| RU (1) | RU2006145961A (es) |
| TW (1) | TW200602042A (es) |
| UY (1) | UY28953A1 (es) |
| WO (1) | WO2005123686A1 (es) |
| ZA (1) | ZA200700156B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026480B2 (en) * | 2001-03-08 | 2006-04-11 | The University Of Hong Kong | Organometallic light-emitting material |
| US20070004644A1 (en) * | 2004-06-09 | 2007-01-04 | Sircar Jagadish C | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | PYRAZOLE DERIVATIVE |
| GB0619611D0 (en) | 2006-10-04 | 2006-11-15 | Ark Therapeutics Ltd | Compounds and their use |
| DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
| US8592592B2 (en) | 2010-04-02 | 2013-11-26 | Senomyx, Inc. | Sweet flavor modifier |
| AU2012295255B2 (en) | 2011-08-12 | 2016-04-21 | Senomyx, Inc. | Sweet flavor modifier |
| CN103497151B (zh) * | 2013-10-30 | 2015-07-15 | 山东铂源药业有限公司 | 一种4-氨基-6-甲基烟酸的合成方法 |
| CA2963901A1 (en) | 2014-11-07 | 2016-05-12 | Senomyx, Inc. | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
| CN106187887B (zh) * | 2016-07-01 | 2018-08-14 | 上海工程技术大学 | 4-羟基喹啉-3-甲酸的制备方法 |
| CN109790170B (zh) | 2016-08-16 | 2022-08-02 | Uwm研究基金会有限公司 | Gaba(a)受体调节剂和控制哮喘中气道高反应性和炎症的方法 |
| CN108623561B (zh) * | 2017-03-24 | 2025-04-01 | 中国海洋大学 | 一种制备哌尼诺酸化合物的方法 |
| CN108456154A (zh) * | 2018-04-13 | 2018-08-28 | 昆明理工大学 | 一种n-叔丁氧羰基烃基胍的制备方法 |
| EP3911640A4 (en) * | 2019-01-18 | 2022-10-26 | Astrazeneca AB | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
| MA54261B1 (fr) * | 2019-01-18 | 2025-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| JPS60136512A (ja) * | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| JPH10316641A (ja) * | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
| AU8334298A (en) * | 1997-07-15 | 1999-02-10 | Novo Nordisk A/S | Nociceptin analogues |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| IL145712A0 (en) * | 1999-04-01 | 2002-07-25 | Esperion Therapeutics Inc | Ether compounds, compositions, and uses thereof |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| FR2820435B1 (fr) * | 2001-02-05 | 2004-02-27 | Genfit S A | Procedes d'identification de composes modulant le transport inverse du cholesterol |
| EP1419770A4 (en) * | 2001-08-24 | 2005-08-03 | Shionogi & Co | AGENT ACC L RATION OF THE EXPRESSION OF APO AI |
| US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| AU2004233333A1 (en) * | 2003-04-22 | 2004-11-04 | Avanir Pharmacueticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
-
2005
- 2005-06-09 EP EP05758578A patent/EP1753724A1/en not_active Withdrawn
- 2005-06-09 CA CA002568394A patent/CA2568394A1/en not_active Abandoned
- 2005-06-09 RU RU2006145961/04A patent/RU2006145961A/ru not_active Application Discontinuation
- 2005-06-09 MX MXJL06000069A patent/MXJL06000069A/es not_active Application Discontinuation
- 2005-06-09 PE PE2005000658A patent/PE20050986A1/es not_active Application Discontinuation
- 2005-06-09 JP JP2007527787A patent/JP2008502736A/ja not_active Withdrawn
- 2005-06-09 US US11/149,067 patent/US20060009487A1/en not_active Abandoned
- 2005-06-09 AR ARP050102363A patent/AR049216A1/es unknown
- 2005-06-09 TW TW094118999A patent/TW200602042A/zh unknown
- 2005-06-09 CN CNA2005800191718A patent/CN1968928A/zh active Pending
- 2005-06-09 UY UY28953A patent/UY28953A1/es not_active Application Discontinuation
- 2005-06-09 WO PCT/US2005/020660 patent/WO2005123686A1/en not_active Ceased
- 2005-06-09 BR BRPI0511822-0A patent/BRPI0511822A/pt not_active Application Discontinuation
- 2005-06-09 AU AU2005255011A patent/AU2005255011A1/en not_active Abandoned
- 2005-06-09 KR KR1020067026459A patent/KR20070026598A/ko not_active Withdrawn
-
2006
- 2006-11-13 IL IL179210A patent/IL179210A0/en unknown
-
2007
- 2007-01-05 ZA ZA200700156A patent/ZA200700156B/en unknown
- 2007-01-08 NO NO20070139A patent/NO20070139L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1753724A1 (en) | 2007-02-21 |
| NO20070139L (no) | 2007-03-08 |
| TW200602042A (en) | 2006-01-16 |
| JP2008502736A (ja) | 2008-01-31 |
| IL179210A0 (en) | 2007-03-08 |
| WO2005123686A1 (en) | 2005-12-29 |
| PE20050986A1 (es) | 2006-02-03 |
| BRPI0511822A (pt) | 2007-12-26 |
| KR20070026598A (ko) | 2007-03-08 |
| MXJL06000069A (es) | 2007-04-10 |
| UY28953A1 (es) | 2006-01-31 |
| AU2005255011A1 (en) | 2005-12-29 |
| RU2006145961A (ru) | 2008-07-20 |
| CA2568394A1 (en) | 2005-12-29 |
| ZA200700156B (en) | 2008-05-28 |
| US20060009487A1 (en) | 2006-01-12 |
| CN1968928A (zh) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049216A1 (es) | Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadas | |
| ECSP21056710A (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar | |
| CL2021003222A1 (es) | (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. | |
| ECSP22040834A (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
| CO2022007172A2 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
| ES2496091T3 (es) | Composiciones de neutralización de malos olores que comprenden ácido undecilénico o ácido cítrico | |
| CO2023016072A2 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| EA201290389A1 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| UY30485A1 (es) | Uso antiviral de un tensioactivo cationico | |
| CY1110751T1 (el) | Φαρμακευτικο σκευασμα που περιλαμβανει μικροκαψουλες απο στατινες εναιωρημενες σε αλκυλεστερες πολυακορεστων λιπαρων οξεων (pufa) | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| NO20071369L (no) | Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv | |
| EP2058317A4 (en) | AMINOOPHOSPHORIC ACID DERTER DERIVATIVE AND THIS ACTIVE MODULATOR OF THE S1P RECEPTOR | |
| AR038385A1 (es) | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo | |
| ATE536170T1 (de) | Verwendung von kationischen tensiden in kosmetischen mitteln | |
| AR072610A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamacion | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| MX2009001200A (es) | Uso antiviral de un tensoactivo cationico. | |
| ECSP099039A (es) | Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares | |
| DK1608346T3 (da) | Lægemiddeltilförselssammensætninger af alfa-hydroxysyreester og fremgangsmåder til anvendelse heraf | |
| NI200700292A (es) | Amidas novedosas derivadas de acidos piperidin carboxilicos | |
| BRPI0606606A2 (pt) | composições estáveis contendo prostaglandina | |
| NO20072998L (no) | Stabilisering av glukokortikoidestere med syrer | |
| NO20084478L (no) | Konjugerte lipidderivater | |
| AR044058A1 (es) | Mediadores peptidicos del transporte inverso de colesterol para el tratamiento de hipercolesterolemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |